Y-Intercept (HK)’s Summit Therapeutics SMMT Stock Holding History

Y-Intercept (HK)’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-119,655	Closed	-$2.27M	–	2132
2026 Q1	$2.27M	Buy	+119,655	New	+$1.94M	0.04%	657
2023 Q2	–	Sell	-39,337	Closed	-$68.8K	–	1691
2023 Q1	$68.8K	Buy	+39,337	New	+$107K	0.01%	1090
2022 Q3	–	Sell	-10,355	Closed	-$10K	–	1247
2022 Q2	$10K	Buy	+10,355	New	+$14.5K	﹤0.01%	814

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Y-Intercept (HK)'s SMMT Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 119,655 shares — an estimated $2.27M sold.

Y-Intercept (HK) first reported a position in SMMT in Q2 2022 and held it in 3 quarters. The position peaked at $2.27M in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Y-Intercept (HK) reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 119,655 Summit Therapeutics shares in Q2 2026, an estimated $2.27M.
Y-Intercept (HK) first reported a position in Summit Therapeutics in Q2 2022 and held it in 3 quarters.
Y-Intercept (HK)'s Summit Therapeutics position peaked at $2.27M in Q1 2026.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.